K. VENKATESWARA RAJU

Dr. K. VENKATESWARA RAJU

REGULATORY AFFAIRS, Shri Vishnu College of Pharmacy, Bhīmavaram, Andhra Pradesh, International
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2025 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
MLMaddala Lohitha
Maddala Lohitha
RVRama Rao Vadapalli
Rama Rao Vadapalli
BBBrahmaiah Bonthagarala
Brahmaiah Bonthagarala
SNSudarshan Rao Nagineni
Sudarshan Rao Nagineni
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
Artificial Intelligence (AI) is ushering in a transformative era for personalized medicine by customizing therapeutic interventions based on individual patient profiles, including genetic information and environmental influences. Through the analysis of intricate biological datasets, AI significantly improves diagnostic accuracy, prognostic assessments and therapeutic planning, thereby enabling more precise patient stratification and enhanced clinical outcomes. This advancement is particularly evident in the realms of genomic analysis and pharmacogenomics. Nonetheless, the integration of AI into healthcare introduces substantial legal and ethical considerations. Foremost among these are concerns related to data privacy, security and equitable access to treatment. It is imperative to address these issues to effectively leverage the full potential of AI. Achieving this requires a reevaluation of regulatory frameworks and an enhancement of training programs for healthcare professionals. As AI continues to advance within the healthcare sector, it promises to fundamentally redefine disease management and prevention, heralding a new epoch of medical innovation.

22 December 2023 in Journal of Young Pharmacists
Verified
Journal Article
Open access
LNLakshmi Prasanthi Nori
Lakshmi Prasanthi Nori
PSPotti Sowmya
Potti Sowmya
TMTippa Madhusree
Tippa Madhusree
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
Lakshmi Prasanthi Nori, Potti Sowmya, Tippa Madhusree and Kalidindi Venkateswara Raju1* Author informationArticle notesCopyright and License informationPDFCitations Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Kovvada, Andhra Pradesh, INDIA Corresponding author. Correspondence:, Dr. K. Venkateswara Raju M. Pharm, Ph.D, Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Kovvada, Andhra Pradesh, INDIA, Email: venkateswararaju.k@svcp.edu.in

7 March 2023 in International Journal of Applied Pharmaceutics
Verified
Journal Article
Open access
PDF file
RPRamya Ponnapalli
Ramya Ponnapalli
MDMantena Sri Lakshmi Divya
Mantena Sri Lakshmi Divya
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
LNLakshmi Prasanthi Nori
Lakshmi Prasanthi Nori
Vaccine development usually takes around 7 y to come to the market after getting necessary regulatory approvals. But recent pandemics like Covid, Ebola, Swine Flu, have resulted in the collaboration of efforts between the government doing investments in vaccine development, academia, regulatory bodies, and industry. This has shortened the timelines for approval for vaccines. In 2009, HINI, Swine flu vaccines took 93 d for identifying the vaccine candidate for clinical trials. In 2014, for Ebola vaccine, it was deployed while the epidemic was still going on. Ebola vaccine was developed in 5 y. In case of Covid (SARS-CoV-2) clinical trials were approved when 2 mo of the pandemic onset. Within a time of 9 mo about 138 vaccine candidates are being reviewed for approval of EUA. This highly helps in the shortening of vaccine development and necessary approval. In this paper, we focused on the regulatory framework of vaccine development in INDIA, US and EU.

21 September 2023 in International Journal of Pharmaceutical Investigation
Verified
Journal Article
Open access
PDF file
LNLakshmi Prasanthi Nori
Lakshmi Prasanthi Nori
SRSheik Rehana
Sheik Rehana
APAnusha Penamacha
Anusha Penamacha
BSBhanu Mounika Somalanka
Bhanu Mounika Somalanka
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
Lakshmi Prasanthi Nori, Sheik Rehana, Anusha Penamacha, Bhanu Mounika Somalanka and K. Venkateswara RajuAuthor informationPDFCitationsCorresponding author. Correspondence: Dr. K. Venkateswara Raju Department of Regulatory Affairs, Shri Vishnu College of Pharmacy, Vishnupur, Bhimavaram, West Godavari-534202, Andhra Pradesh, INDIA. Email: venkateswararaju.k@svcp.edu.in Author NotesReceived March 30, 2023; Revised April 20, 2023; Accepted May 01, 2023.Copyright and License informationCopyright

1 January 2024 in Brazilian Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
SRSheik Rehana
Sheik Rehana
SSSarvan Manikiran Seethamraju
Sarvan Manikiran Seethamraju
LNLAKSHMI PRASANTHI NORI
LAKSHMI PRASANTHI NORI
In the biopharmaceutical industry, the conventional “linear and sequential” clinical trial approach is still the norm; however, it is frequently beset by issues with patient selection, retention, and monitoring that are not up to par, leading to longer trial durations and higher trial failure rates. Artificial intelligence (AI) has the potential to reduce the duration of clinical trials significantly, expedite protocol design and study implementation, improve trial outcomes, and lower the cost of biopharmaceutical R&D. AI may also speed up clinical cycle times. Clinical trial mining, design and execution, and real-world experience analysis are all possible using AI. Major drug makers are utilizing AI to locate volunteers for clinical trials or to cut down on the number of subjects required for drug testing, which might speed up medication development and save millions of dollars. The clinical trial procedure may be enhanced by AI, but evidentiary requirements for a drug’s efficacy and safety won’t alter, according to regulators. This article discusses the application of AI, RWD, and RWE in clinical trials and how it is transforming the biopharma value chain, encompassing all pharmaceutical firms referred to as “biopharma companies” due to the inclusion of biologics in their development pipelines and within these biopharma firms, artificial intelligence (AI) is finding its way into drug research.

28 September 2016 in Indian Journal of Science and Technology
Verified
Journal Article
Open access
PDF file
KRK. VENKATESWARA RAJU
K. VENKATESWARA RAJU
DKD. Prasanna Kumar
D. Prasanna Kumar
A Study on Impulse Buying Behaviour in the Backdrop of Customer Perception towards Visual Merchandising and Other Service Attributes at Organized Retail Outlets in Hyderabad